xCures has partnered with the DIPG and DMG Research Funding Alliance (DDRFA) to support the recruitment of patients with these rare CNS cancers into a natural history study (xPedite) with the
ultimate goal of ending randomization in clinical trials.
xCures has partnered with the DIPG and DMG Research Funding Alliance (DDRFA) to support the recruitment of patients with these rare CNS cancers into a natural history study (xPedite) with the
ultimate goal of ending randomization in clinical trials.